(Q37313166)

19 August 2017

title

Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection (English)

1 reference

19 August 2017

1 reference

3

Raymond T Chung

1 reference

19 August 2017

Barbara H McGovern

1

1 reference

19 August 2017

Barham K Abu Dayyeh

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

48

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

1700-1712

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

19 August 2017

cites work

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

21 January 2018

1 reference

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

21 January 2018

1 reference

Unravelling hepatitis C virus replication from genome to function

21 January 2018

1 reference

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

21 January 2018

1 reference

Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors

21 January 2018

1 reference

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

21 January 2018

1 reference

Challenges and successes in developing new therapies for hepatitis C.

21 January 2018

1 reference

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

21 January 2018

1 reference

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

21 January 2018

1 reference

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

21 January 2018

1 reference

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo

21 January 2018

1 reference

Cyclophilin inhibitors in hepatitis C viral infection

21 January 2018

1 reference

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

21 January 2018

1 reference

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

21 January 2018

1 reference

Hepatitis C virus genetic variability: pathogenic and clinical implications

21 January 2018

1 reference

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

21 January 2018

1 reference

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

21 January 2018

1 reference

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

21 January 2018

1 reference

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

21 January 2018

1 reference

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication

21 January 2018

1 reference

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b

21 January 2018

1 reference

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

21 January 2018

1 reference

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

21 January 2018

1 reference

Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop

21 January 2018

1 reference

Resisting resistance: maximizing the durability of antiretroviral therapy.

21 January 2018

1 reference

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

21 January 2018

1 reference

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen

21 January 2018

1 reference

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

21 January 2018

1 reference

Pharmacokinetic enhancement of protease inhibitor therapy

21 January 2018

1 reference

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

21 January 2018

1 reference

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

21 January 2018

1 reference

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

21 January 2018

1 reference

Sequencing antiretroviral drugs

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.22563

1 reference

19 August 2017

1 reference